Literature DB >> 25245016

Decade in review-hepatocellular carcinoma: HCC-subtypes, stratification and sorafenib.

Gregory J Gores1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25245016      PMCID： PMC5526453          DOI： 10.1038/nrgastro.2014.157

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

Authors:  Chien-Jen Chen; Hwai-I Yang; Jun Su; Chin-Lan Jen; San-Lin You; Sheng-Nan Lu; Guan-Tarn Huang; Uchenna H Iloeje
Journal:  JAMA       Date:  2006-01-04       Impact factor: 56.272

2.  Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times.

Authors:  Khairuddin Memon; Laura Kulik; Robert J Lewandowski; Edward Wang; Ahsun Riaz; Robert K Ryu; Kent T Sato; Karen Marshall; Ramona Gupta; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Seanthan Senthilnathan; Talia Baker; Vanessa L Gates; Michael Abecassis; Al B Benson; Mary F Mulcahy; Reed A Omary; Riad Salem
Journal:  Gastroenterology       Date:  2011-04-30       Impact factor: 22.682

3.  Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.

Authors:  Vincenzo Mazzaferro; Josep M Llovet; Rosalba Miceli; Sherrie Bhoori; Marcello Schiavo; Luigi Mariani; Tiziana Camerini; Sasan Roayaie; Myron E Schwartz; Gian Luca Grazi; René Adam; Peter Neuhaus; Mauro Salizzoni; Jordi Bruix; Alejandro Forner; Luciano De Carlis; Umberto Cillo; Andrew K Burroughs; Roberto Troisi; Massimo Rossi; Giorgio E Gerunda; Jan Lerut; Jacques Belghiti; Ilka Boin; Jean Gugenheim; Fedja Rochling; Bart Van Hoek; Pietro Majno
Journal:  Lancet Oncol       Date:  2008-12-04       Impact factor: 41.316

4.  Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Kenneth K Tanabe; Antoinette Lemoine; Dianne M Finkelstein; Hiroshi Kawasaki; Tsutomu Fujii; Raymond T Chung; Gregory Y Lauwers; Yakup Kulu; Alona Muzikansky; Darshini Kuruppu; Michael Lanuti; Jonathan M Goodwin; Daniel Azoulay; Bryan C Fuchs
Journal:  JAMA       Date:  2008-01-02       Impact factor: 56.272

5.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

6.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Authors:  Yujin Hoshida; Augusto Villanueva; Masahiro Kobayashi; Judit Peix; Derek Y Chiang; Amy Camargo; Supriya Gupta; Jamie Moore; Matthew J Wrobel; Jim Lerner; Michael Reich; Jennifer A Chan; Jonathan N Glickman; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Maria G Daidone; Sasan Roayaie; Myron Schwartz; Swan Thung; Helga B Salvesen; Stacey Gabriel; Vincenzo Mazzaferro; Jordi Bruix; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  N Engl J Med       Date:  2008-10-15       Impact factor: 91.245

7.  A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection.

Authors:  Jean-Charles Nault; Aurélien De Reyniès; Augusto Villanueva; Julien Calderaro; Sandra Rebouissou; Gabrielle Couchy; Thomas Decaens; Dominique Franco; Sandrine Imbeaud; Francis Rousseau; Daniel Azoulay; Jean Saric; Jean-Frédéric Blanc; Charles Balabaud; Paulette Bioulac-Sage; Alexis Laurent; Pierre Laurent-Puig; Josep M Llovet; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2013-04-06       Impact factor: 22.682

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Authors:  Jean Charles Nault; Maxime Mallet; Camilla Pilati; Julien Calderaro; Paulette Bioulac-Sage; Christophe Laurent; Alexis Laurent; Daniel Cherqui; Charles Balabaud; Jessica Zucman-Rossi; Jessica Zucman Rossi
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  Keratin 19: a key role player in the invasion of human hepatocellular carcinomas.

Authors:  Olivier Govaere; Mina Komuta; Johannes Berkers; Bart Spee; Carl Janssen; Francesca de Luca; Aezam Katoonizadeh; Jasper Wouters; Léon C van Kempen; Anne Durnez; Chris Verslype; Joery De Kock; Vera Rogiers; Leo A van Grunsven; Baki Topal; Jacques Pirenne; Hugo Vankelecom; Frederik Nevens; Joost van den Oord; Massimo Pinzani; Tania Roskams
Journal:  Gut       Date:  2013-08-19       Impact factor: 23.059
  10 in total
  23 in total

Review 1.  Emerging role of silent information regulator 1 (SIRT1) in hepatocellular carcinoma: a potential therapeutic target.

Authors:  Yuting Wu; Xiaoming Meng; Cheng Huang; Jun Li
Journal:  Tumour Biol       Date:  2015-05-01

2.  SOX4 activates CXCL12 in hepatocellular carcinoma cells to modulate endothelial cell migration and angiogenesis in vivo.

Authors:  Chi-Neu Tsai; Shu-Chuan Yu; Chao-Wei Lee; Jong-Hwei Su Pang; Chun-Hsin Wu; Sey-En Lin; Yi-Hsiu Chung; Chia-Lung Tsai; Sen-Yung Hsieh; Ming-Chin Yu
Journal:  Oncogene       Date:  2020-05-13       Impact factor: 9.867

3.  DNA Hypomethylation and Histone Variant macroH2A1 Synergistically Attenuate Chemotherapy-Induced Senescence to Promote Hepatocellular Carcinoma Progression.

Authors:  Michela Borghesan; Caterina Fusilli; Francesca Rappa; Concetta Panebianco; Giovanni Rizzo; Jude A Oben; Gianluigi Mazzoccoli; Chris Faulkes; Illar Pata; Antonella Agodi; Farhad Rezaee; Shane Minogue; Alessandra Warren; Abigail Peterson; John M Sedivy; Julien Douet; Marcus Buschbeck; Francesco Cappello; Tommaso Mazza; Valerio Pazienza; Manlio Vinciguerra
Journal:  Cancer Res       Date:  2016-01-15       Impact factor: 12.701

4.  The aryl hydrocarbon receptor agonist benzo(a)pyrene reactivates LINE-1 in HepG2 cells through canonical TGF-β1 signaling: implications in hepatocellular carcinogenesis.

Authors:  Elsa M Reyes-Reyes; Irma N Ramos; Marco A Tavera-Garcia; Kenneth S Ramos
Journal:  Am J Cancer Res       Date:  2016-05-01       Impact factor: 6.166

5.  Histone variant macroH2A1 rewires carbohydrate and lipid metabolism of hepatocellular carcinoma cells towards cancer stem cells.

Authors:  Oriana Lo Re; Julien Douet; Marcus Buschbeck; Caterina Fusilli; Valerio Pazienza; Concetta Panebianco; Carlo Castruccio Castracani; Tommaso Mazza; Giovanni Li Volti; Manlio Vinciguerra
Journal:  Epigenetics       Date:  2018-09-29       Impact factor: 4.528

6.  BCORL1 is an independent prognostic marker and contributes to cell migration and invasion in human hepatocellular carcinoma.

Authors:  Guozhi Yin; Zhikui Liu; Yufeng Wang; Changwei Dou; Chao Li; Wei Yang; Yingmin Yao; Qingguang Liu; Kangsheng Tu
Journal:  BMC Cancer       Date:  2016-02-15       Impact factor: 4.430

7.  Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.

Authors:  Tian-Yi Zhou; Lin-Han Zhuang; Yan Hu; Yu-Lu Zhou; Wen-Kai Lin; Dan-Dan Wang; Zi-Qian Wan; Lin-Lin Chang; Ying Chen; Mei-Dan Ying; Zi-Bo Chen; Song Ye; Jian-Shu Lou; Qiao-Jun He; Hong Zhu; Bo Yang
Journal:  Sci Rep       Date:  2016-08-01       Impact factor: 4.379

8.  Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma.

Authors:  Simone Jueliger; John Lyons; Sara Cannito; Illar Pata; Pille Pata; Marianna Shkolnaya; Oriana Lo Re; Marion Peyrou; Francesc Villarroya; Valerio Pazienza; Francesca Rappa; Francesco Cappello; Mohammad Azab; Pietro Taverna; Manlio Vinciguerra
Journal:  Epigenetics       Date:  2016-09-20       Impact factor: 4.528

9.  Long Noncoding RNA lncCAMTA1 Promotes Proliferation and Cancer Stem Cell-Like Properties of Liver Cancer by Inhibiting CAMTA1.

Authors:  Li-Juan Ding; Yan Li; Shu-Dong Wang; Xin-Sen Wang; Fang Fang; Wei-Yao Wang; Peng Lv; Dong-Hai Zhao; Feng Wei; Ling Qi
Journal:  Int J Mol Sci       Date:  2016-09-23       Impact factor: 5.923

10.  High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.

Authors:  Yinzong Xiao; Lunquan Sun; Yongming Fu; Yan Huang; Rongrong Zhou; Xingwang Hu; Pengcheng Zhou; Jun Quan; Ning Li; Xue-Gong Fan
Journal:  BMC Cancer       Date:  2017-12-15       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.